Figure 2. The monoclonal antibody for human PDGFR inhibited skeletal tumor growth.

IMC-3G3 is effective in counteracting the progression of established skeletal metastases. After mice were inoculated with prostate cancer cells, treatment was withheld from mice for either one or two weeks, after which treatment of IMC-3G3 was maintained for the remainder of the experiment. When mice were euthanized at four weeks, their tibiae and femora showed a significant reduction in the average size of bone tumors as compared to controls[37]. This figure is reprinted with permision from Russell et al. [37], Clinical Cancer Research, 2010, 16 (2):5002–5010. Copyright© 2010 by American Association for Cancer Research.